Artificial intelligence-driven virtual knockout in cancer research: Progress, challenges, and future perspectives
Year: 2026
Type: article
Abstract: Artificial intelligence-driven virtual knockout is emerging as an intervention-oriented computational paradigm that helps move cancer research from descriptive association toward perturbation-informed hypothesis generation and model-derived counterfactual prediction. Virtual knockout simulates biologically meaningful loss-of-function perturbations in genes, pathways, or regulatory nodes. This approach facilitates target prioritization, model-based mechanistic interpretation, screening of combinatorial strategies, and optimization of downstream validation before experimental intervention. In this review, we define virtual knockout as a class of computational frameworks that model the consequences of loss-of-function perturbations and estimate model-derived post-perturbation biological states, while distinguishing strict virtual knockout models from related perturbation-inference paradigms. We summarize major modeling strategies, including gene regulatory network perturbation, trajectory and transcription factor program modeling, generative model-derived counterfactual prediction, constraint-based metabolic simulation, and communication-informed perturbation analysis, and review their applications in driver gene prioritization, context-specific vulnerability discovery, resistance-associated rewiring, tumor microenvironment analysis, metastasis-associated regulator prioritization, drug development, and patient-oriented therapeutic prioritization. We further propose a four-level evidence framework (L1-L4) and discuss major challenges, including data sparsity, tumor heterogeneity, context dependence, and cross-platform inconsistency. Overall, virtual knockout represents a promising bridge between computational inference, experimental validation, and precision oncology, although its current role is best viewed as one of prioritization and decision support rather than direct clinical replacement.
Source: The Innovation Oncology
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W7169569017